Ascendis Pharma Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM EDTOppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
September 4, 2024 5:18 AM EDTJefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $174.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Skytrofa experienced a revenue growth reversal in Q2 (26M; -58% Q/Q; -25% YoY) on an unexpected net price... More
Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
September 4, 2024 5:06 AM EDTGoldman Sachs analyst Paul Choi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "Miss for Skytrofa on the back of insurance contract resets and significant price pressure; focus remains on upcoming US... More
Ascendis Pharma (ASND) PT Lowered to $178 at Citi
September 4, 2024 4:57 AM EDTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 2Q24 financial results, missing Street estimates on topline revenue and GAAP EPS as the company made significant accounting... More
